Abiopharma

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Nuvation Bio Inc. - Nuvation Bio To Present New Data onIBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

New Form 10-Q - MESA LABORATORIES INC /CO/ Filed: 2025-08-05 AccNo: 0001437749-25-024715 Size: 6 MB

Talkspace Announces Second Quarter 2025 Results

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Allurion - Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

New Form 8-K - Talkspace, Inc. Filed: 2025-08-05 AccNo: 0000950170-25-102417 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Harmony Biosciences Holdings, Inc. Filed: 2025-08-05 AccNo: 0001558370-25-010182 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - NOVANTA INC Filed: 2025-08-05 AccNo: 0000950170-25-102416 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Wave Life Sciences Ltd. Filed: 2025-08-05 AccNo: 0001193125-25-173053 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025

New Form 8-K - MESA LABORATORIES INC /CO/ Filed: 2025-08-05 AccNo: 0001437749-25-024714 Size: 316 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

Lucid Diagnostics to Participate in Upcoming Investor Conferences